Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T Cells in Mantle Cell Lymphoma
NCT02081937Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2014
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-T cells in mantle cell lymphoma (MCL), sponsored by Chinese PLA General Hospital. Primary endpoints: Occurrence of study related adverse events at 2 years and Duration of in vivo survival of CART-19 cells. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02081937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081937.